Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $834.48 million. The enterprise value is $274.38 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 88.77 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Current Share Class | 88.77M |
| Shares Outstanding | 88.77M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 1.60% |
| Owned by Institutions (%) | 78.16% |
| Float | 70.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.60 |
| Forward PS | 6.55 |
| PB Ratio | 8.39 |
| P/TBV Ratio | 7.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.15, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.15 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -216.74 |
Financial Efficiency
Return on equity (ROE) is -124.74% and return on invested capital (ROIC) is -76.99%.
| Return on Equity (ROE) | -124.74% |
| Return on Assets (ROA) | -28.45% |
| Return on Invested Capital (ROIC) | -76.99% |
| Return on Capital Employed (ROCE) | -57.66% |
| Weighted Average Cost of Capital (WACC) | 5.96% |
| Revenue Per Employee | $275,535 |
| Profits Per Employee | -$1.13M |
| Employee Count | 260 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $79,000 in taxes.
| Income Tax | 79,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +63.45% in the last 52 weeks. The beta is 0.32, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +63.45% |
| 50-Day Moving Average | 9.17 |
| 200-Day Moving Average | 9.27 |
| Relative Strength Index (RSI) | 46.06 |
| Average Volume (20 Days) | 1,904,410 |
Short Selling Information
The latest short interest is 15.64 million, so 17.62% of the outstanding shares have been sold short.
| Short Interest | 15.64M |
| Short Previous Month | 15.43M |
| Short % of Shares Out | 17.62% |
| Short % of Float | 22.24% |
| Short Ratio (days to cover) | 11.69 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $71.64 million and -$294.57 million in losses. Loss per share was -$3.35.
| Revenue | 71.64M |
| Gross Profit | -189.04M |
| Operating Income | -317.75M |
| Pretax Income | -294.49M |
| Net Income | -294.57M |
| EBITDA | -316.60M |
| EBIT | -317.75M |
| Loss Per Share | -$3.35 |
Full Income StatementBalance Sheet
The company has $580.82 million in cash and $24.27 million in debt, with a net cash position of $556.55 million or $6.27 per share.
| Cash & Cash Equivalents | 580.82M |
| Total Debt | 24.27M |
| Net Cash | 556.55M |
| Net Cash Per Share | $6.27 |
| Equity (Book Value) | 107.88M |
| Book Value Per Share | 1.22 |
| Working Capital | 522.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.99 million and capital expenditures -$6.47 million, giving a free cash flow of -$84.46 million.
| Operating Cash Flow | -77.99M |
| Capital Expenditures | -6.47M |
| Depreciation & Amortization | 1.15M |
| Net Borrowing | n/a |
| Free Cash Flow | -84.46M |
| FCF Per Share | -$0.95 |
Full Cash Flow StatementMargins
| Gross Margin | -263.88% |
| Operating Margin | -443.54% |
| Pretax Margin | -411.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.08% |
| Shareholder Yield | -1.08% |
| Earnings Yield | -35.45% |
| FCF Yield | -10.16% |
Analyst Forecast
The average price target for Kura Oncology is $31.17, which is 231.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.17 |
| Price Target Difference | 231.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of -2.44 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.44 |
| Piotroski F-Score | 1 |
